Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | FCER2 | P06734 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026533 | 0.87 | FCER2 (0.48) | MEN1KMT2AFCER2MMP9TRPV1 | |
| SCHEMBL29687069 | 0.80 | FPR2 (0.62) | MEN1KMT2ATHRBRAB9ANPC1 | |
| SCHEMBL14026535 | 0.77 | TACR1 (0.54) | FCER2MMP9 | |
| SCHEMBL7655882 | 0.72 | CTSS (0.69) | FCER2MMP9 | |
| SCHEMBL8740509 | 0.72 | CTSS (0.69) | FCER2MMP9 | |
| SCHEMBL9331930 | 0.72 | CTSS (0.69) | FCER2MMP9 | |
| SCHEMBL14026106 | 0.72 | L3MBTL1 (0.46) | MEN1KMT2AFCER2 | |
| SCHEMBL14026113 | 0.71 | HPGDS (0.45) | FCER2 | |
| SCHEMBL761191 | 0.71 | FCER2 (0.55) | FCER2MMP9 | |
| SCHEMBL30995920 | 0.71 | FCER2 (0.63) | FCER2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | OPRL1, TRPV1, ORAI1 | MEN1 4198/4885KMT2A 2244/4885FCER2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.